Verastem, Inc.

Good afternoon and welcome to VeriSTEM Oncology's first quarter 2026 earnings conference call. My name is Daniel and I will be your call operator today. Please note this event is being recorded. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. I will now turn the call over to Julissa Vianna Vice President of Corporate Communications, Investor Relations, and Patient Advocacy for Verisim Oncology.

Please go ahead. Thank you, operator.

Welcome, everyone, and thank you for joining us today to discuss Verisim's first quarter 2026 financial results. and recent business updates. This afternoon, we issued a press release detailing these results, along with the slide presentations that will be referenced during our call today. Both are available on the investor relations section of our website. Before we begin, let me point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. we encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today we will be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today. Joining me on today's call to deliver prepared remarks and take your questions are Dan Patterson, President and CEO, Dr. Michael Kaufman, President of Development, and Dan Calkins, Chief Financial Officer. I will now turn the call over to Dan.